Kornitzer Capital Management Inc. KS Sells 135,636 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Kornitzer Capital Management Inc. KS lessened its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 25.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 407,238 shares of the company's stock after selling 135,636 shares during the period. Kornitzer Capital Management Inc. KS owned 1.48% of Castle Biosciences worth $11,614,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of CSTL. Principal Financial Group Inc. lifted its position in shares of Castle Biosciences by 2.7% in the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company's stock worth $43,879,000 after buying an additional 40,377 shares during the last quarter. Perkins Capital Management Inc. lifted its holdings in Castle Biosciences by 5.0% in the 3rd quarter. Perkins Capital Management Inc. now owns 32,640 shares of the company's stock worth $931,000 after purchasing an additional 1,550 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in Castle Biosciences by 11.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 153,907 shares of the company's stock worth $4,389,000 after purchasing an additional 15,200 shares during the last quarter. US Bancorp DE boosted its position in Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company's stock worth $132,000 after purchasing an additional 4,383 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Castle Biosciences by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company's stock valued at $152,000 after purchasing an additional 2,093 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group boosted their price objective on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a research note on Tuesday, October 29th. Robert W. Baird boosted their target price on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a research report on Tuesday. Lake Street Capital lifted their price objective on Castle Biosciences from $34.00 to $40.00 and gave the stock a "buy" rating in a research note on Tuesday. BTIG Research raised their target price on Castle Biosciences from $35.00 to $40.00 and gave the company a "buy" rating in a report on Monday, October 14th. Finally, KeyCorp upped their price target on Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a report on Tuesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $37.88.

Castle Biosciences Stock Performance

Shares of CSTL stock traded up $0.65 during mid-day trading on Thursday, reaching $33.31. The stock had a trading volume of 386,069 shares, compared to its average volume of 324,662. Castle Biosciences, Inc. has a one year low of $16.20 and a one year high of $35.84. The firm has a market cap of $919.69 million, a PE ratio of 168.06 and a beta of 0.99. The firm's 50 day simple moving average is $30.78 and its 200 day simple moving average is $25.72. The company has a quick ratio of 7.92, a current ratio of 8.12 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a return on equity of 1.50% and a net margin of 1.95%. The firm had revenue of $85.78 million during the quarter, compared to analysts' expectations of $78.55 million. During the same period last year, the business earned ($0.26) earnings per share. On average, analysts forecast that Castle Biosciences, Inc. will post -0.58 EPS for the current year.

Insider Transactions at Castle Biosciences

In related news, insider Derek J. Maetzold sold 986 shares of the stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $28.73, for a total value of $28,327.78. Following the completion of the transaction, the insider now owns 94,622 shares of the company's stock, valued at $2,718,490.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Tobin W. Juvenal sold 3,507 shares of the company's stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $35.56, for a total value of $124,708.92. Following the sale, the insider now owns 54,178 shares of the company's stock, valued at approximately $1,926,569.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Derek J. Maetzold sold 986 shares of Castle Biosciences stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $28.73, for a total transaction of $28,327.78. Following the transaction, the insider now directly owns 94,622 shares of the company's stock, valued at $2,718,490.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 23,201 shares of company stock valued at $688,206. Company insiders own 7.20% of the company's stock.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.